Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
1.580
-0.020 (-1.25%)
At close: May 6, 2026, 4:00 PM EDT
1.580
0.00 (0.00%)
Pre-market: May 7, 2026, 5:27 AM EDT
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,595,434
Market Cap
2.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 5 | 0 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2023 | 4 | -16 | -80.00% | 4 | 0 |
| Dec 31, 2022 | 20 | -1 | -4.76% | 16 | 4 |
| Dec 31, 2021 | 21 | 12 | 133.33% | 16 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 19 |
| Silexion Therapeutics | 14 |
| Biodexa Pharmaceuticals | 11 |
| Artelo Biosciences | 7 |
ADIL News
- 7 days ago - Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 - GlobeNewsWire
- 9 days ago - Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program - GlobeNewsWire
- 14 days ago - Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - GlobeNewsWire
- 3 months ago - Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 7 months ago - Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show - GlobeNewsWire